Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03502746 · OUTCOME

Progression-free Survival (PFS)

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma · Source last updated 2024-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Time of treatment start until the criteria for disease progression or death, up to a maximum of 23 months.

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from treatment start until disease progression met by RECIST 1.1 or death from any cause.

Groups in this outcome

Nivolumab + Ramucirumab

Nivolumab 240mg IV + Ramucirumab 8mg/kg IV Nivolumab: Nivolumab 240mg, IV over 30 minutes. Ramucirumab: 8mg/kg, IV over 60 minutes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab + Ramucirumab34

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab + Ramucirumab4.2Not reported1.96.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        6.4
        value
        4.2
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from treatment start until disease progression met by RECIST 1.1 or death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Nivolumab 240mg IV + Ramucirumab 8mg/kg IV Nivolumab: Nivolumab 240mg, IV over 30 minutes. Ramucirumab: 8mg/kg, IV over 60 minutes.
    id
    OG000
    title
    Nivolumab + Ramucirumab
param Type
MEDIAN
reporting Status
POSTED
time Frame
Time of treatment start until the criteria for disease progression or death, up to a maximum of 23 months.
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice